Andreessen Horowitz Bio + Health
Overview
Andreessen Horowitz (a16z) Bio + Health invests in bold entrepreneurs who are innovating new ways to treat and tackle diseases and building the modern, efficient, and enduring healthcare system for better care. The fund focuses on therapeutic platforms and cutting-edge technology companies that can bring new medicines and disease treatments to improve patients' lives. They invest in companies at all stages, from company creation to growth, and take a long-term view to enable disruptive companies to realize the full potential of new biological science, engineering technologies, and AI capabilities.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Stipple Bio | Apr 2026 | Series A | Lead |
| Gate Bioscience | Nov 2025 | Series B | Co-investor |
| knownwell | Oct 2025 | Early Funding | Co-investor |
| Thyme Care | Sep 2025 | Series D | Lead |
| Sprinter Health | May 2025 | Series B | Co-investor |
Key People
Andrew Chen
General Partner
Erik Torenberg
General Partner
Jeff Jordan
General Partner At A16z
Katherine Boyle
General Partner
Charles Payton
Partner, Capital Formation Investor Relations
David Garcia
Partner, Investor Relations
Erika Louie
Partner, HR
Marci Rosalez
Partner, Growth Events
Mario Linares
Partner-Executive Talent
Robert Weber
Partner, Technical Talent
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
